Atractylenolide-I Ameliorates Motor Deficits and Reduces Inflammation of the Spinal Cord by SIRT1/PGC-1α Pathway in MPTP Subacute Mouse Model of Parkinson’s Disease [Letter]

We read with great interest the recent study by Gao et al exploring the therapeutic potential of Atractylenolide-I (ATR-I) in a Parkinson's disease (PD) mouse model.The authors provide valuable insights into ATR-I's role in alleviating motor deficits and reducing inflammation in the MPTP-induced PD mouse model. 1 We particularly appreciate the authors' focus on the SIRT1/PGC-1 pathway and their thorough investigation into the neuroprotective effects of ATR-I.Gao et al demonstrate that ATR-I not only mitigates motor deficits in the MPTP-induced subacute PD model but also prevents dopaminergic (DA) neuron loss in the substantia nigra pars compacta (SNpc).Additionally, the study shows that ATR-I suppresses microglial activation in both the SNpc and spinal cord.The upregulation of SIRT1/PGC-1-related proteins in the spinal cord is particularly noteworthy, and the authors suggest that ATR-I has broad neuroprotective properties, positioning it as a promising candidate for PD treatment.While this study is both comprehensive and impressive, we believe several aspects warrant further discussion to strengthen the conclusions and clarify the mechanisms involved.Firstly, ATR-I is known to exert anti-inflammatory effects through multiple pathways, including ERK1/2, p38, and NF-B signaling. 2While the authors focus on the SIRT1/PGC-1 pathway, the study did not directly confirm whether ATR-I's beneficial effects are dependent on this specific pathway.A more definitive demonstration would involve using specific inhibitors of SIRT1 or PGC-1 to validate whether ATR-I's action is indeed mediated through this pathway.Furthermore, the role of upstream regulators, such as NAD+ levels, 3 and downstream effectors, such as genes involved in mitochondrial biogenesis, 4 remains unexplored.Investigating these factors would provide a more comprehensive understanding of how ATR-I modulates the SIRT1/PGC-1 pathway and exerts its neuroprotective effects.Moreover, the study employed only a single dose of ATR-I (30 mg/kg), which limits the ability to assess dose-response relationships.It is well established that varying doses of therapeutic agents can lead to differential activation of cellular pathways, including the SIRT1/PGC-1 axis, and thus may result in distinct therapeutic outcomes.Future studies would benefit from a doseresponse analysis to determine the optimal therapeutic window for ATR-I, ensuring both efficacy and safety.In conclusion, while Gao et al study provides important insights into the therapeutic potential of ATR-I in PD, 1 addressing the aforementioned points would further enhance the rigor and depth of their findings.We believe these considerations will contribute to the translational potential of ATR-I as a viable therapeutic strategy for PD.